Study of two targeted drugs for B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a combination of two drugs, inotuzumab and blinatumomab, for people with B-cell acute lymphoblastic leukemia (B-ALL). It may be an option for newly diagnosed patients who are older or unable to tolerate standard chemotherapy, or for patients whose leukemia has returned or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your leukemia cells must have CD19 and CD22 markers (proteins on the surface).
- You either have newly diagnosed leukemia and are 55 or older, or are 18-54 with health issues that make standard chemo risky, or your leukemia has come back or not responded to treatment.
- Your kidneys, liver, and heart function must meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a full course of immunotherapy (drugs that help your immune system fight cancer) instead of intensive chemotherapy for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older or cannot tolerate strong chemo. It aims to offer an effective, less toxic option.
This trial tests a subcutaneous (under the skin) form of blinatumomab for people with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of leukemia cells that can be detected by sensitive tests. The goal is to see if this treatment is safe and can get rid of those remaining cells.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
Hear when a new B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.